Marcy Silver

TL;DR: It is suggested that EC progenitors may be useful for augmenting collateral vessel growth to ischemic tissues (therapeutic angiogenesis) and for delivering anti- or pro-angiogenic agents, respectively, to sites of pathologic or utilitarianAngiogenesis.

TL;DR: Findings indicate that postnatal neovascularization does not rely exclusively on sprouting from preexisting blood vessels (angiogenesis); instead, EPCs circulate from bone marrow to incorporate into and thus contribute to postnatal physiological and pathological neov vascularization, which is consistent with postnatal vasculogenesis.

TL;DR: Findings indicate that circulating EPCs are mobilized endogenously in response to tissue ischemia or exogenously by cytokine therapy and thereby augment neovascularization of ischemic tissues.

TL;DR: Ex vivo expanded hEPCs may have utility as a "supply-side" strategy for therapeutic neovascularization in mice with hindlimb ischemia and the rate of limb loss was significantly reduced.

TL;DR: A novel role is established for VEGF in postnatal neovascularization which complements its known impact on angiogenesis and is based on data from animal models and human subjects.